Cosentyx (Secukinumab)
Cosentyx Sensoready Pen 150mg/ml
Secukinumab
Select product strength & quantity:
Cosentyx pre-filled syringe 150mg/ml
Secukinumab
Select product strength & quantity:

Prescription Required.

Product of Canada.

Express Ships from Canada.

Prescription Required.
Product of Canada.
Express Ships from Canada.

Cosentyx (Secukinumab)

What is Cosentyx (Secukinumab)?

Cosentyx (secukinumab) is a human interleukin-17A antagonist medication that is administered via subcutaneous injection for the treatment of plaque psoriasis that is moderate to severe, psoriatic arthritis, non-radiographic axial spondyloarthritis, active ankylosing spondylitis, and enthesis-related arthritis. This medication is most commonly injected once every four weeks for treatment.

How is Cosentyx Used?

As a subcutaneous injection, this medication will need to be injected just underneath the skin. The injection may be given in the abdomen, in the upper arm, or in the thigh, and the injection site should be rotated each time the medication is administered. Cosentyx should not be injected directly into any skin areas that are red, inflamed, bruised, damaged, or impacted by psoriasis. Patients should be sure to wash their hands well before using their prefilled syringe or SensoReady pen.

As this medication does not contain preservatives and requires refrigeration, patients preparing to inject their scheduled dose are advised to remove the medication from the refrigerator directly before use and allow the solution within the SensoReady pens or prefilled syringes to come to room temperature. This medication should be injected within one hour after it has been removed from refrigeration. The needle cap should not be removed from the device or syringe until right before the patient is about to inject the medication.

Before injection, patients should be sure to visually check the solution to ensure that there is no cloudiness, discoloration, or particles floating within the syringe or SensoReady pen. If the solution does not appear to be clear or simply yellow-tinted and somewhat opalescent in appearance, it should not be used. Additionally, any used portions of Cosentyx should be discarded after the patient has injected their prescribed dose.

Patients may receive their first injection in their doctor’s office so they may receive proper instruction from medical personnel regarding how to safely give themselves the injections at home. Afterward, many patients using the prefilled syringes and SensoReady pens are able to perform the monthly injections by themselves. Pediatric patients should not self-administer their scheduled doses of Cosentyx and should receive assistance from an adult who has received the appropriate training to allow them to perform the injections for the child.

Storage

This medication should be refrigerated and stored in temperatures ranging between 36°F (2°C) and 46°F (8°C). The SensoReady pens and prefilled syringes should be stored in their original packaging and kept away from any exposure to light until they are ready to be used.

This medication should not be frozen and should not be shaken before use due to the potential for foaming to occur. There are no preservatives in this medicine, so any unused portions should be disposed of after a patient has injected the prescribed amount of Cosentyx for treatment.

If refrigeration is not possible in some circumstances (e.g., during travel), this medication may be exposed to room temperatures, without exceeding 86°F (30°C), for a maximum of four days. If your prefilled syringes or SensoReady pens have been kept in temperatures below 86°F for less than four days, they may be placed back into refrigeration for later use. If this medication is exposed to temperatures that are above the maximum of 86°F (30°C), or it has not been used within the 4-day period after being removed from refrigeration, it should be discarded.

Keep this medication out of the reach of children at all times.

Uses

Cosentyx is prescribed for the treatment of the following conditions:

  • Plaque psoriasis (moderate to severe)
  • Psoriatic arthritis
  • Active ankylosing spondylitis
  • Non-radiographic axial spondyloarthritis
  • Enthesis-related arthritis

How Does Cosentyx Work?

Most of the conditions for which this medication is prescribed are caused by the overproduction of a protein known as interleukin-17A (IL-17A) within the body. As an interleukin-17A antagonist, Cosentyx targets this particular protein and inhibits its activity, thereby reducing the effects of this protein on the various conditions caused by its overproduction. This results in a decrease in the associated symptoms of excess interleukin-17A.

Dosage

Cosentyx is an injection that is available in the following strengths and forms:

  • 75 mg/mL injection (prefilled syringe, single dose)
  • 150 mg/mL injection (prefilled syringe, single dose)
  • 150 mg/mL injection (SensoReady Pen)

The dosage that a patient will be prescribed will be determined based on a number of different health factors as well as the condition for which it has been prescribed to treat.

When used for the treatment of plaque psoriasis in adult patients, the most common dosage of Cosentyx is two injections of the medication administered weekly for a period of five weeks. After this initial phase, they will then be on a regular dose of two injections every four weeks.

Patients using this medication for the treatment of psoriatic arthritis may have an initial loading dose of one injection per week for a period of five weeks, after which they will be moved to a dosing schedule of one injection every four weeks.

Patients with both of these conditions occurring comorbidly will often be prescribed the higher dosage of Cosentyx used in the treatment of plaque psoriasis by itself.

Individuals with non-radiographic axial spondyloarthritis or ankylosing spondylitis may or may not be required to begin treatment with the standard loading dose of Cosentyx, which involves one weekly injection for a period of five weeks. However, not all patients with these two conditions will be required to have this initial loading dose. Most commonly, patients with either of these conditions will be prescribed a dosage of one injection to be administered once every four weeks. Some patients with ankylosing spondylitis that do not experience improvement in their symptoms may have their dosage increased to two injections administered once every four weeks.

Those who are using Cosentyx in the treatment of enthesis-related arthritis will typically also begin with the weekly dosage of one injection per week for a period of five weeks before proceeding to the common dosing schedule of one injection administered once every four weeks.

Children that use this medication will have their dosage determined based on their current body weight. However, they will often have the same dosing schedule as those receiving one injection weekly for a five-week period, who then maintain a dosing schedule of one injection every four weeks.

Overdose

If an overdose has occurred or is suspected, patients should contact their physician or their local Poison Control Center for assistance. If an individual has overdosed on Cosentyx and is experiencing serious side effects, such as difficulties with breathing or losing consciousness, emergency medical attention should be sought immediately.

Side Effects

The most common side effects of taking Cosentyx are as follows:

  • cold sores
  • cold symptoms
  • diarrhea
  • runny nose
  • sneezing
  • sore throat
  • stuffy nose

Some of the following side effects may also occur and should be discussed with your doctor:

  • athlete’s foot
  • infection of the eye
    • swelling
    • redness
    • itchiness
    • discharge
  • itchy rash
  • symptoms of infection
    • chills
    • diarrhea (severe)
    • dizziness (severe or prolonged)
    • fever
    • headaches
    • neck stiffness
    • shortness of breath
    • weight loss
  • thrush (white patches that occur in the mouth)

Please seek emergency medical attention if you are using Cosentyx and experience any of the following symptoms of an allergic reaction to the medication:

  • abdominal cramping
  • breathing difficulties
  • nausea
  • swelling of the throat or face
  • vomiting

Warnings & Precautions

Allergic Reactions

Some individuals using this medication have experienced significant allergic reactions during treatment. If you experience any of the following symptoms of an allergic reaction while using Cosentyx, stop using the medication and consult with your prescribing physician as soon as possible: breathing difficulties, hives, swelling of the throat or face, or a severe rash. If these symptoms occur and become severe and life-threatening, seek emergency medical attention immediately.

Infection Risk

This medication is associated with an increased risk of patients developing certain infections, some of which may be severe. Patients with diabetes or other conditions that may impact their immunity should inform their doctor of these conditions before beginning treatment with Cosentyx. Any individual using this medication that develops symptoms of an infection should report this to their doctor as soon as possible. Special monitoring may be required in some cases.

Irritable Bowel Syndrome

Patients with inflammatory bowel conditions may experience a worsening of their symptoms and overall condition when using this medication. Those with a history of inflammatory bowel disease should be sure to discuss the potential side effects of Cosentyx as it relates to their bowel conditions with their physician before beginning treatment.

Latex Allergies

Patients with a known allergy or sensitivity to latex are advised to discuss this with their physician before beginning treatment with Cosentyx. The removable cap on both the SensoReady pens and the prefilled syringes consists of a material that is chemically similar to latex and may place these individuals at risk of experiencing a reaction. However, there have been no studies to determine the exact risks involved for those who have an allergy or sensitivity to latex, so these individuals should discuss the possibility of an allergic reaction with their doctor before using one of the prefilled syringes or SensoReady pens.

Pediatric Patients

This medication may be used to treat plaque psoriasis in pediatric patients above the age of 12 years or that weigh more than 100 lbs. Its safety and efficacy in those below this age and weight range have not been determined. Although it may be prescribed for pediatric patients to manage plaque psoriasis, Cosentyx has not been approved to treat ankylosing spondylitis or psoriatic arthritis in those below the age of 18 years.

Pregnancy and Breastfeeding

This medication should not be used by pregnant individuals unless their doctor has specifically deemed the benefits of using Cosentyx to outweigh the potential risks of this medication related to an unborn and developing child. Patients currently using this medication that become pregnant should inform their doctor as soon as possible.

It has not been determined if Cosentyx passes into breast milk.

Vaccines

Due to the impaired immunity and increased infection risk associated with using this medication, patients are advised to avoid receiving any live vaccines during treatment, such as those for yellow fever or BCG. If any vaccinations are required while actively using Cosentyx, patients should be sure to discuss all potential health risks with their physician before receiving any vaccines.

Additional Medical Conditions

If you have any of the following medical conditions, exercise caution when taking Cosentyx and discuss your medical history with your doctor before beginning this medication:

  • any current infections
  • any recent infections
  • bowel disease
  • Crohn’s disease
  • herpes
  • returning infections
  • tuberculosis
  • ulcerative colitis

Drug Interactions

Speak to your doctor about any medications or herbal supplements you are currently taking before beginning treatment with this medication. Discuss any concerns you may have with your doctor or a trusted pharmacist.

The following medications and substances are known to interact with Cosentyx:

  • bacillus Calmette-Guerin (BCG)
  • baricitinib
  • belimumab
  • cladribine
  • denosumab
  • echinacea
  • fingolimod
  • infliximab
  • leflunomide
  • natalizumab
  • ocrelizumab
  • ozanimod
  • pimecrolimus
  • roflumilast
  • siponimod
  • tacrolimus
  • tofacitinib
  • upadacitinib
  • vaccines

Alternative Medications

For patients who are unable to take Cosentyx or experiencing significant adverse side effects, alternative medications may be used to treat some of the associated conditions for which this medication is commonly prescribed:

  • adalimumab (Humira)
  • apremilast (Otezla)
  • certolizumab pegol (Cimzia)
  • etanercept (Enbrel)
  • guselkumab (Tremfya)
  • infliximab (Remicade)
  • ixekizumab (Taltz)
  • ustekinumab (Stelara)

Frequently Asked Questions

Cosentyx is an interleukin-17A antagonist that is administered via subcutaneous injection. It is used in the treatment of plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, active ankylosing spondylitis, and enthesis-related arthritis.

This medication is different from other similar medications available on the market due to it being a biologic that targets the IL-17A molecule within the body.

This medication has been FDA-approved for the treatment of moderate to severe plaque psoriasis since 2015. As of 2016, it was also approved for use in individuals with ankylosing spondylitis and psoriatic arthritis. In 2020, the FDA approved Cosentyx to treat individuals with non-radiographic axial spondylarthritis as well.

This medication is administered subcutaneously via a prefilled syringe or the SensoReady Pen device. The patient should inject the medication just underneath the skin in the abdomen, in the upper arm, or in the thigh. Most patients using Cosentyx will self-administer their prescribed dosage of the medication via injection once every four weeks.

Whether a patient is using either the SensoReady pen or the prefilled syringe, this medication should be injected just underneath the skin of the patient’s thigh, upper arm, or abdomen. The injection site should be rotated each time the medication is administered, and it should never be injected into skin that is damaged, red, inflamed, or affected by psoriasis. Due to the medication requiring refrigeration, patients should also remove their prefilled syringe or SensoReady pen from the refrigerator about 30 minutes before using it and allow the solution to come to room temperature. This medicine will need to be injected within one hour after removing it from refrigeration.

The efficacy will vary depending on the condition for which it has been prescribed. Those using Cosentyx for plaque psoriasis have seen significant skin clearance within 12 weeks of treatment. When used for psoriatic arthritis, about 60% of those using the medication in a study experienced a 20% improvement in their condition and its associated symptoms after about 16 weeks of treatment. Those using the medication for ankylosing spondylitis reported improvement within about 16 weeks as well.

The recommended dosage of this medication will vary based on the condition for which it has been prescribed. Although an individual’s specific dosage may vary, the most common dosing schedule for any patient using Cosentyx is one to two injections performed every four weeks after an initial phase or more frequent use. Please consult with your prescribing physician if you have any questions regarding your prescribed dosage.

The most common side effects of using this medication include upper respiratory infections and diarrhea.

Most patients notice an improvement in their condition within several weeks after beginning treatment with this medication.

Patients that are prescribed a 300 mg dose of Cosentyx will need to administer two injections of the 150 mg prefilled syringes or SensoReady pens to meet the required dosage determined by their physician.

This medication is used in the treatment and management of plaque psoriasis (moderate to severe), ankylosing spondylitis, active psoriatic arthritis, and non-radiographic axial spondyloarthritis (nraxSpA).

No changes in weight have been reported as side effects in those using this medication. Similar medications to Cosentyx have been linked to weight changes, but patients using this medication typically do not experience any weight gain or weight loss during treatment. If you are currently using this medication and have unexplained changes in your weight, please consult with your prescribing physician.

Although this medication reduces the inflammation within a patient’s body in a similar way as TNF inhibitors do, Cosentyx is a monoclonal antibody. The results of using this medication may be similar to a TNF inhibitor, but the function of the medication itself is different.

The active ingredient in Cosentyx is secukinumab. The inactive ingredients in both the prefilled syringes as well as the SensoReady pens include the following: sterile water, trehalose dihydrate, polysorbate 80, L-methionine, and L-histidine/histidine hydrochloride monohydrate.

This medication is not currently approved for the treatment of eczema. However, its safety and efficacy when used to manage this condition are currently being studied, so it may become available and approved for use in those who have eczema in the future.

Yes. If a patient is unable to use or tolerate Cosentyx for any reason, the following alternative medications for treatment are also available: adalimumab (Humira), apremilast (Otezla), certolizumab pegol (Cimzia), etanercept (Enbrel), guselkumab (Tremfya), infliximab (Remicade), ixekizumab (Taltz), and ustekinumab (Stelara).

Overdosing on this medication may result in serious side effects. If an overdose is suspected or has occurred, the individual’s physician or local Poison Control Center should be contacted as soon as possible. If symptoms of an allergic reaction or side effects that are severe occur after using too much of this medication, emergency medical attention should be sought immediately.

Yes, Cosentyx (secukinumab) does require refrigeration. It should be stored in a refrigerator between 2°C and 8°C (36°F and 46°F). It is important to keep Cosentyx in its original packaging and protect it from light. If you accidentally leave it out of the refrigerator for a short period of time, it can be returned to the refrigerator as long as it hasn’t been exposed to high temperatures for an extended period. However, it is always best to follow the specific storage instructions provided by your healthcare provider or the manufacturer. If you have any doubts or questions, it is recommended to consult your healthcare professional for further guidance.